drugset / Trial / NCT06801249
Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome
RandomizedParallel-groupOpen-labelTreatment
Summary
Drug interventional, controlled, randomized open-label, parallel-group, multicenter study in patients with bilateral adrenal incidentalomas associated with subclinical Cushing's syndrome
Timeline
- Start
- 2021-02-23
- Primary completion
- 2024-11-30
- Completion
- 2025-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metirapone | Unknown | 250 mg | — |
| Subject | Metirapone | Unknown | 750 mg | — |